請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32999
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳進庭(Chin-Tin Chen) | |
dc.contributor.author | Shang-Chih Chen | en |
dc.contributor.author | 陳尚志 | zh_TW |
dc.date.accessioned | 2021-06-13T04:21:29Z | - |
dc.date.available | 2008-07-28 | |
dc.date.copyright | 2006-07-28 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-21 | |
dc.identifier.citation | Aisner DL, Wright WE, Shay JW(2002) Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev. 12(1):80-5.
Ash DV, Brown SB(1993)News drugs and future developments in photodynamic therapy. Eur J Cancer 29:1781–3. Barker CR, McNamara AV, Rackstraw SA, Nelson DE, White MR, Watson AJ, Jenkins JR(2006)Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage. Nucleic Acids Res. 34(4):1148-57. Beck WT, Mo YY, Bhat UG(2001) Cytotoxic signalling by inhibitors of DNA topoisomerase II. Biochem Soc Trans. 29(Pt 6):702-3. Berenbaum MC, Bonnett R, Chevretton EB, Akande- Adebakin SL, Ruston M. (1993)Selectivity of mesotetra(hydroxyphenyl) porphyrins and chlorins and of Photofrin II in causing photodamage in tumour, skin, muscle and bladder; the concept of cost–benefit in analysing the results. Laser Med Sci 8:235–43. Bonnett R, Charlesworth P, Djelal BD, Foley S, McGarvey DJ and Truscott TG (1999) Photophysical properties of 5,10,15,20-tetrakis(m-hydroxyphenyl)-porphyrin (m-THPP) and 5,10,15,20-tetrakis(m-hydroxyphenyl)bacterio-chlorin (m-THPBC): a comparative study. J. Chem. Soc., Perkin Trans. 2:325–328. Bonnett R, White RD, Winfield UJ, and MC (1989) Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers.Biochem J. 261(1): 277–280. Boyle R.W. and Dolphin D. (1996) Structure and biodistribution relationships of photodynamic sensitizers. Photochem. Photobiol. 64:469–485. Chang CC, Kuo IC, Ling IF, Chen CT, Chen HC, Lou PJ, Lin JJ, Chang TC(2004) Detection of quadruplex DNA structures in human telomeres by a fluorescent carbazole derivative. Anal Chem. 1;76(15):4490-4. Chang CC, Kuo, IC, Lin JJ, Lu YC, Chen CT, Back HT, Lou PJ, and Chang TC (2004) BMVC, a novel carbazole derivative and potential antitumor agent, as a potent telomerase inhibitor and selective fluorescence marker of cancer cells. Chem. & Biodiv.1:1377-1384. Chang CC, Wu JY, Chien CW, Wu WS, Liu H, Kang CC, Yu LJ, Chang TC (2003) A fluorescent carbazole derivative: high sensitivity for quadruplex DNA. Anal Chem.15;75(22):6177-83. Cong YS, Wright WE, Shay JW Human (2002)Telomerase and its regulation. Microbiol Mol Biol Rev. 66(3):407-25. Coutier S, Bezdetnaya L, Marchal S, Melnikova V, Belitchenko I, Merlin JL and Guillemin F (1999) Foscan (mTHPC) photosensitized macrophage activation: enhancement of phagocytosis, nitric oxide release and tumour necrosis factor-alpha-mediated cytolytic activity. Br. J. Cancer 81:37–42. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al.(1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo.Proc Natl Acad Sci USA.92(20):9363-7. Dolmans DE, Fukumura D, Jain RK(2003) Photodynamic therapy for cancer. Nat Rev Cancer. 3(5):380-7. Eom YW, Kim MA, Park SS, Goo MJ, Kwon HJ, Sohn S, Kim WH, Yoon G, Choi KS(2005) Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype.Oncogene.14;24(30):4765-77. Epe B. Genotoxicity of singlet oxygen(1991) Chem Biol Interact 80:239-260. Errington F, Willmore E, Tilby MJ, Li L, Li G, Li W, Baguley BC, Austin CA(1999) Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol. 56(6):1309-16. Famulski KS, Halloran PF(2005) Molecular events in kidney ageing. Curr Opin Nephrol Hypertens. 14(3):243-8. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW.(2006)Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat. 96(1):73-81. Hayflick L (1974)The strategy of senescence. Gerontologist. 14(1):37-45. His RA, Rosenthal DI, Glatstein E(1999) Photodynamic therapy in the treatment of cancer. Drugs.57:725-734. Hornung R, Fink D, Dobler-Girdziunaite D, Stallmach T, Haller U and Walt H (1999) Photodynamic therapy for the hypercalcemic type of the small cell carcinoma of the ovary in a mouse xenograft model. Gynecol. Oncol. 75:447–452. Hornung R, Jentsch B, Crompton NE, Haller U, Walt H(1997)In vitro effects and localisation of the photosensitizers m-THPC and m-THPC MD on carcinoma cells of the human breast (MCF-7) and Chinese hamster fibroblasts (V-79). Lasers Surg Med. 20(4):443-50. Jazwinski SM, Howard BH, Nayak RK(1995) Cell cycle progression, aging, and cell death. J Gerontol A Biol Sci Med Sci. 50A(1):B1-8. Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D, Hickson ID(1992)Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24.Nucleic Acids Res. 20(21):5587-92. Kalka K, Merk H, Mukhtar H(2000) Photodynami therapy in dermatology. J Am Acad Dermatol. 42:389-413. Kato H(1996) History of photodynamic therapy--past, present and future. Gan To Kagaku Ryoho. 23(1):8-15. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. (2002) Culprit and victim -- DNA topoisomerase II. Lancet Oncol. 3(4):235-43. Koechli OR, Schaer GN, Schenk V, Haller U, Walt H (1995) Assessment of effect of photosensitizers on cytotoxicity of photodynamic therapy in human breast cancer cell cultures. Arch. Gynecol. Obstet. 256:167–176. Ma L, Moan J, Berg K (1994) Evaluation of a new photosensitizer, meso-tetra-hydroxyphenyl-chlorin, for use in photodynamic therapy: a comparison of its photobiological properties with those of two other photosensitizers. Int. J. Cancer 57:883–888. Mak CK, Hung VK, Wong JT (2005) Type II topoisomerase activities in both the G1 and G2/M phases of the dinoflagellate cell cycle.Chromosoma. 114(6):420-31. Martinez-Cayuela M(1995) Oxygen free radicals and human disease. Biochimie. 77(3):147-61. Meeker AK, De Marzo AM (2004)Recent advances in telomere biology: implications for human cancer. Curr Opin Oncol. 16(1):32-8. Melnikova VO, Bezdetnaya LN, Potapenko AY, Guillemin F (1999) Photodynamic properties of meta-tetra(hydroxyphenyl)chlorin in human tumor cells. Radiat. Res. 152:428–435. Morlet L, Vonarx-Coinsmann V, Lenz P, Foultier MT, de Brito LX, Stewart C, Patrice T. (1995) Correlation between meta(tetrahydroxyphenyl)chlorin (m-THPC) biodistribution and photodynamic effects in mice. J. Photochem. Photobiol. B: Biol. 28, 25–32. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM(1997)5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer. 79(12):2282-308. Pereira-Smith OM, Smith JR(1988) Genetic analysis of indefinite division in human cells: identification of four complementation groups. Proc Natl Acad Sci U S A. 85(16):6042-6. Pervaiz S (2001)Reactive oxygen-dependent production of novel photochemotherapeutic agents. FASEB J. 15(3):612-7. Ris HB, Altermati HJ, Nachbur B et al.(1993) Effect of drug-light interval on photodynamic therapy with m-Tetrahydroxyphenylchlorin in malignant mesothelioma.Int J Cancer 53:141–6. Ris HB, Altermati HJ, Nachbur B et al.(1993) Photodynamic therapy with meta-tetrahydroxyphenylchlorin in vivo: optimization of the therapeutic index. Int J Cancer 55:245–9. Slyshenkov VS, Shevalye AA, Liopo AV, Wojtczak L(2002) Protective role of L-methionine against free radical damage of rat brain synaptosomes. Acta Biochim Pol. 49(4):907-16. Tahara H, Shin-Ya K, Seimiya H, Yamada H, Tsuruo T, Ide T (2006)G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells. Oncogene. 25(13):1955-66. Teiten MH, Bezdetnaya L, Merlin JL, Bour-Dill C, Pauly ME, Dicato M, Guillemin F (2001) Effect of meta-tetra(hydroxyphenyl)chlorin (mTHPC) -mediated photodynamic therapy on sensitive and multidrug-resistant human breast cancer cells. J Photochem Photobiol B. 62(3):146-52. Tsai-Pflugfelder M, Gasser SM, Wahli W(1998) Functional interaction between the estrogen receptor and CTF1: analysis of the vitellogenin gene B1 promoter in yeast.Mol Endocrinol. 12(10):1525-41. Urquidi V, Tarin D, Goodison S (2000) Role of telomerase in cell senescence and oncogenesis. Annu Rev Med. 51:65-79. Wang JC(2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 3(6):430-40. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2(4):209-14. Xiong Y(1996) Why are there so many CDK inhibitors? Biochim Biophys Acta. 1288(1):01-5. Yin F, Liu J, Peng X(2004) Effects of triethylene tetraamine on telomerase activity and proliferation in HeLa cells. Cell Biol Int. 28(4):287-91. Zhao N, Huang G, Guo L, Lu SH(2006) ECRG1, a novel candidate of tumor suppressor gene in the esophageal carcinoma, triggers a senescent program in NIH3T3 cells. Exp Biol Med (Maywood) 231(1):84-90. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32999 | - |
dc.description.abstract | 現今癌症的治療方式,最主要障礙是在於化學治療藥劑的非專一性毒殺細胞而造成的副作用。絕大部分的癌細胞藉由端粒酶來維持端粒的長度而生存及進行不正常增生,而大多數的正常細胞缺乏端粒酶。倘若能藉由抑制端粒酶作用,選擇性地對癌細胞產生毒殺,而不對正常細胞有威脅,此種策略不啻為可行的方法。
BMVC 【3,6-bis(1-methyl-4-vinylpyridinium)carbazole diiodide】可與人類端粒上四股結構 (G-quadruplex)中的d(T2AG3)序列形成穩定的鍵結。在本研究中,我們利用人類子宮頸癌上皮細胞(HeLa),經由BMVC處理下,來探討所造成生物效應變化之情形。研究結果顯示:(1)BMVC會明顯抑制癌細胞的生長。(2)長時間與BMVC培養的細胞,其生長會受到抑制,但主要原因非衰老此單一因素所造成。(3)BMVC進入癌細胞的量為正常細胞的兩倍以上。(4)BMVC在細胞中累積的位置,在癌細胞中主要在細胞核。(5)經BMVC培養的癌細胞,其細胞週期由G1 phase 進入 S phase有受到延遲的現象。(6)BMVC會影響Topoisomerase II解開超螺旋DNA。 由於BMVC具有抑制癌細胞生長的能力,可利用此種性質,來研究BMVC相關光感物質對癌細胞的生物機制。探討PS-BMVC與meto-tera (hydroxyphenyl) porphyrin衍生物在細胞存在的量與位置,及光動力治療效果。 | zh_TW |
dc.description.abstract | Presently, the major obstacle of cancer chemotherapy is the non-specific cytotoxicity of chemotherapeutic drugs. Over 80% of cancer cells maintain telomere length by telomerase, which are not found in normal somatic cells. Therefore telomerase inhibitor could induce selective cytotoxicity on tumor cell.
3,6-bis(1-methyl-4-vinylpyridinium)carbazole diiodide (BMVC) has been synthesized and shown to stabilize the G-quadruplex structure of human telomeric sequence of d(T2AG3). The purpose of this study is to investigate the biological effects of BMVC on HeLa cell. We found: (1) The growth of tumor cells was inhibited by BMVC. (2) The long-term effects in population doubling showed that the growth inhibition of BMVC and the shortening of telomere by BMVC might not play the major role in the inhibition of cell growth. (3) Compared to normal cells, cancer cells have higher uptake of BMVC. (4) BMVC was mainly localized in the nucleus of cancer cells (5) BMVC suppressed the cell progression cycle into S-phase. (6) BMVC could interfere to form relax induced by Topoisomerase II. Furthermore, we investigated the cellular location, uptake, and photodynamic effects of BMVC analogs and Meto-tera (hydroxyphenyl) porphyrin derived analogs. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T04:21:29Z (GMT). No. of bitstreams: 1 ntu-95-R93450012-1.pdf: 6310222 bytes, checksum: 94cde7d5651bd1584bc86a771259d955 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 縮寫表……………………………………………………………… 1
中文摘要…………………………………………………………… 2 英文摘要…………………………………………………………… 4 緒論………………………………………………………………… 6 實驗材料與方法……………………………………………………20 結果…………………………………………………………………29 第一部份………………………………………………………29 第二部份………………………………………………………35 第三部份………………………………………………………38 第四部份………………………………………………………41 討論…………………………………………………………………47 結論…………………………………………………………………53 圖表…………………………………………………………………54 參考文獻……………………………………………………………89 | |
dc.language.iso | zh-TW | |
dc.title | BMVC及相關光感物質所引發細胞毒性及機制探討 | zh_TW |
dc.title | Investigation of the Cellular Cytotoxicity and Action Mechanism Induced by BMVC and Related Photosensitizers | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蔡翠敏(Tsuimin-Tsai),陳啟祥 | |
dc.subject.keyword | 細胞毒性,光感物質,端粒,衰老,拓樸酶, | zh_TW |
dc.subject.keyword | BMVC,cytotoxixity,photosensitizer,mTHPP,telomere,senescence,topoisomerase, | en |
dc.relation.page | 95 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 6.16 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。